Nelson J. Chao, MD

Related Content

Services

• Adult Bone Marrow Transplant
• Emergency Services
• Transplants

Chief

Department / Division:
Medicine / Cellular Therapy

Address:
DUMC 3961
Durham, NC 27710

Appointment Telephone:
(919) 668-1000

Office Telephone:
(919) 668-1010

Fax Telephone:
(919) 668-1091

• M.D., Yale University School of Medicine, Connecticut, 1981

• Medicine, Stanford University Medical Center, California, 1981-1984
• Oncology, Stanford University Medical Center, California, 1985-1987

Clinical Interests:
Hematology, oncology, bone marrow transplantation

Research Interests:
My research interests are in two broad areas, clinical hematopoietic stem cell and cord blood transplantation and in the laboratory studies related to graft vs. host disease and immune reconstitution.  On the clinical side we are currently conducting approximately 50 different clinical protocols ranging from preparatory regimens, supportive care studies and disease specific protocols. Most of these clinical studies are centered around studies of the sources of stem cells and the methods to improve the long term outcome.  There are exploratory protocols for novel therapies such as dendritic cell therapy for several malignancies, antiangiogenesis therapy, graft engineering to prevent graft-versus-host disease and antigen specific T cells or non specific NK cells to prevent relapse.  Moreover a strong focus of the program is to develop cord-blood transplantation for adult patients with hematologic malignancies.  The laboratory studies center on understanding the immunological events that occur with graft-vs-host disease and methods to prevent this disease.  The current efforts focus on understanding murine reconstitution following transplantation, use of a peptide polymer to block MHC class II recognition of minor histocompatibility antigens, use of T cell engineering to prevent graft-versus-host disease at the same time preserving a graft-versus-malignancy effect.

For more information see http://ed-media.mc.duke.edu/BMT.nsf

Representative Publications:
Schlegel PG, Vaysburd M, Chen Y, Butcher E, Chao NJ. Selective inhibition of T cell costimulation mediated by VCAM-1 prevents murine graft-versus-host disease. Journal of Immunology, 155: 3856-3865, 1995. (1995)

Schriber JR, Chao NJ, Long GD, Negrin RS, Tierney DK, Kusnierz-Glaz C, Lucas KS, and Blume KG. Granulocyte colony stimulating factor (G-CSF) following allogeneic bone marrow transplantation. Blood, 84:1680-1684, 1994. (1994)

Schlegel PG,Schlegel PG; Aharoni R; Smilek DE; Fernandez LP; McDevitt HO; Tran N; Vaysburd M; Chao NJ. Prevention of graft-versus-host disease by synthetic peptides with high binding affinity for class II MHC molecules.Blood, 84:2802-2810, 1994. (1994)

Chao NJ. Graft-versus-Host Disease: Past, Present, and Future. RP Landes Company, Austin, TX, 1994. (1994)

, (1994)

Horning SJ, Negrin RS, Chao NJ, Long GD, Hoppe RT, and Blume KG. Fractionated total body irradiation, etoposide and cyclophosphamide and autografting in Hodgkin's disease and non-Hodgkin's lymphoma. J. Clin Oncol, 12:2552-2558, 1995. (1995)

Fernandez LP, and Chao NJ. Lack of effect of thalidomide on IL-2 response and production. Experimental Hematology, 23:978-85, 1995. (1995)

Schlegel PG, Vaysburd M, Chen Y, Butcher E, Chao NJ. Selective inhibition of T cell costimulation mediated by VCAM-1 prevents murine graft-versus-host disease. Journal of Immunology, 155: 3856-3865, 1995. (1995)

Chao NJ, Blume KG, Forman SJ, and Snyder DS. Long term follow-up of allogeneic BMT for Philadelphia chromosome positive acute lymphoblastic leukemia. Blood 88:3353-4 [letter], 1995. (1995)

Chao NJ. Prevention and treatment of graft-versus-host disease. In On Call in...Bone Marrow Transplantation. Ed: Burt RK, Deeg J, Santos G. R. G. Landes, Austin, TX, 1995. (1995)

Behar E, Chao NJ, Hiraki D, Krishnaswamy S, Zehnder J, and Grumet FC. Polymorphism of adhesion molecule CD31 and its association with graft vs. host disease. New England Journal of Medicine, 334:286-291, 1996. (1996)

Chen Y, Schlegel PG, Tran N, Thompson D, Zehnder J, Chao NJ. Administration of a CD31-derived peptide delays the onset and significantly increases survival from lethal graft-versus-host disease. Blood, 89 (4): 1452-1459, 1997. (1997)

Chao, N Graft-vs-host disease: The viewpoint from the donor T cell. Biology of Blood and Marrow Transplantation 3:1-10, 1997 (1997)

MANUSCRIPTS IN PRESS (1997)

Kohler S, Hendrickson MR, Chao NJ, Smoller BR. Value of Skin Biopsies in Assessing Prognosis and Progression of Acute Graft- Versus-Host Disease. American Journal of Surgical Pathology, in press. (1997)

Chao, NJ. Graft-versus-Host Disease. In Up to Date. Ed Rose B. Wellesley, MA, 1998. Chao, NJ. Pharmacological Prevention of Graft-vs-Host disease. In: Bone Marrow Transplantation. Eds. Forman, S.J., Thomas, E.D. Blume, K.G. Blackwell Scientific Publications, Inc., New York, 1998. (1998)

Chen Y, Zeng D, Schlegel PG, Fedler J, Chao NJ. PG27, An Extract of Tripterygium Wilfordii Hook F., Induces Antigen Specific Tolerance in Bone Marrow Transplantation in Mice. Blood, 95:705-710, 1999. (1999)

Aharoni R, Schlegel PG, Teitelbaum D, Roikhel-Karpov O, Chen Y, Arnon R, Sela M, Chao NJ. Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease. Immunol Lett. 1997 Jul;58(2):79-87. (1997) Abstract

Blume KG, Schmidt GM, Chao NJ, Forman SJ. Bone marrow transplantation from histocompatible sibling donors for patients with acute lymphoblastic leukemia. Hamatol Bluttransfus. 1990;33:636-7. (1990) Abstract

Chao NJ. Graft versus host disease following allogeneic bone marrow transplantation. Curr Opin Immunol. 1992 Oct;4(5):571-6. (1992) Abstract

Goker H, Haznedaroglu IC, Chao NJ. Acute graft-vs-host disease: pathobiology and management. Exp Hematol. 2001 Mar;29(3):259-77. (2001) Abstract

Chao NJ, Tierney DK, Bloom JR, Long GD, Barr TA, Stallbaum BA, Wong RM, Negrin RS, Horning SJ, Blume KG. Dynamic assessment of quality of life after autologous bone marrow transplantation. Blood. 1992 Aug 1;80(3):825-30. (1992) Abstract

Chen BJ, Cui X, Chao NJ. Addition of a second, different allogeneic graft accelerates white cell and platelet engraftment after T-cell-depleted bone marrow transplantation. Blood. 2002 Mar 15;99(6):2235-40. (2002) Abstract

Chao NJ, Blume KG. Bone marrow transplantation. Part I--Allogeneic. West J Med. 1989 Dec;151(6):638-43. (1989) Abstract

Chao NJ, Amylon MD, Long GD, Negrin RS, Hoppe RT, Horning SJ, Blume KG. Bone marrow transplantation for hematologic malignancies: the Stanford experience. Clin Transpl. 1990;:157-63. (1990) Abstract

Schmidt-Wolf IG, Aihara M, Negrin RS, Blume KG, Chao NJ. Lymphokine-activated killer cell activity after cryopreservation. J Immunol Methods. 1989 Dec 20;125(1-2):185-9. (1989) Abstract

Ross M, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD, Nademanee AP, Negrin RS, O'Donnell MR, Parker PM, Smith EP, Snyder DS, Stein AS, Wong RM, Forman SJ, Blume KG, Chao NJ. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival. Biol Blood Marrow Transplant. 1999;5(5):285-91. (1999) Abstract

Long GD, Negrin RS, Hoyle CF, Kusnierz-Glaz CR, Schriber JR, Blume KG, Chao NJ. Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies. Cancer. 1995 Sep 1;76(5):860-8. (1995) Abstract

Chao NJ, Schlegel PG. Prevention and treatment of graft-versus-host disease. Ann N Y Acad Sci. 1995 Dec 29;770:130-40. (1995) Abstract

Chen BJ, Liu C, Cui X, Fidler JM, Chao NJ. Prevention of graft-versus-host disease by a novel immunosuppressant, PG490-88, through inhibition of alloreactive T cell expansion. Transplantation. 2000 Nov 27;70(10):1442-7. (2000) Abstract

Chao NJ, Blume KG. Bone marrow transplantation. Part II--autologous. West J Med. 1990 Jan;152(1):46-51. (1990) Abstract

Chen BJ, Chen Y, Cui X, Fidler JM, Chao NJ. Mechanisms of tolerance induced by PG490-88 in a bone marrow transplantation model. Transplantation. 2002 Jan 15;73(1):115-21. (2002) Abstract

Aihara M, Sikic BI, Blume KG, Chao NJ. Assessment of purging with multidrug resistance (MDR) modulators and VP-16: results of long-term marrow culture. Exp Hematol. 1990 Sep;18(8):940-4. (1990) Abstract

Chao NJ. Graft-versus-host disease: the viewpoint from the donor T cell. Biol Blood Marrow Transplant. 1997 Apr;3(1):1-10. (1997) Abstract

Schmidt GM, Niland JC, Forman SJ, Fonbuena PP, Dagis AC, Grant MM, Ferrell BR, Barr TA, Stallbaum BA, Chao NJ. Extended follow-up in 212 long-term allogeneic bone marrow transplant survivors. Issues of quality of life. Transplantation. 1993 Mar;55(3):551-7. (1993) Abstract

Marie JP, Brophy NA, Ehsan MN, Aihara Y, Mohamed NA, Cornbleet J, Chao NJ, Sikic BI. Expression of multidrug resistance gene mdr1 mRNA in a subset of normal bone marrow cells. Br J Haematol. 1992 Jun;81(2):145-52. (1992) Abstract

Chao NJ. Progress in graft-versus-host disease. J Hematother Stem Cell Res. 2000 Jun;9(3):295-6. (2000) Abstract

Chao NJ, Blume KG. Bone marrow transplantation: what is the question? Ann Intern Med. 1990 Sep 1;113(5):340-1. (1990) Abstract

Schmidt-Wolf IG, Aihara M, Negrin RS, Blume KG, Chao NJ. In vitro and in vivo activity of murine lymphokine-activated killer cells after cryopreservation. Transfusion. 1992 Jan;32(1):42-5. (1992) Abstract

Chao NJ, Rosenberg SA, Horning SJ. CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma. Blood. 1990 Oct 1;76(7):1293-8. (1990) Abstract

Chao NJ, Stein AS, Long GD, Negrin RS, Amylon MD, Wong RM, Forman SJ, Blume KG. Busulfan/etoposide--initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia. Blood. 1993 Jan 15;81(2):319-23. (1993) Abstract

Chao NJ. Mobilization of peripheral blood progenitor cells by hematopoietic growth factors. Can J Oncol. 1995 Dec;5 Suppl 1:43-6. (1995) Abstract

Morse MA, Rizzieri D, Stenzel TT, Hobeika AC, Vredenburgh JJ, Chao NJ, Clay TM, Mosca PJ, Lyerly HK. Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants. J Hematother Stem Cell Res. 2002 Aug;11(4):659-68. (2002) Abstract

Chao NJ, Long GD, Negrin RS, Schriber JR, Raimondi CM, Brown SL, Blume KG. G-CSF and peripheral blood progenitor cells. Lancet. 1992 Jun 6;339(8806):1410. (1992) Abstract

Nieto Y, Cagnoni PJ, Shpall EJ, Xu X, Murphy J, Vredenburgh J, Chao NJ, Bearman SI, Jones RB. A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant. Clin Cancer Res. 1999 Nov;5(11):3425-31. (1999) Abstract

Shbarou RM, Chao NJ, Morgenlander JC. Cyclosporin A-related cerebral vasculopathy. Bone Marrow Transplant. 2000 Oct;26(7):801-4. (2000) Abstract

Chao NJ, Aihara M, Kühl JS, Sikic BI, Blume KG. Purging multidrug resistant cells from bone marrow. Prog Clin Biol Res. 1992;377:13-23. (1992) Abstract

Chao NJ, Schmidt GM, Niland JC, Amylon MD, Long GD, Nademanee AP, Negrin RS, O'Donnell MR, Parker PM, Smith EP, Snyder DS, Stein AS, Wong RM, Blume KG, and Forman SJ. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. New England Journal of Medicine, 327:1225- 1230, 1993. (1993)

Schlegel PG, Aharoni R, Chen Y, Chen J, Teitelbaum D, Arnon R, Sela M, Chao NJ. A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo. Proceedings of the National Academy of Sciences (USA), 93:5061-5066, 1996. (1996)

Behar E, Chao NJ, Hiraki D, Krishnaswamy S, Zehnder J, and Grumet FC. Polymorphism of adhesion molecule CD31 and its association with graft vs. host disease. New England Journal of Medicine, 334:286-291, 1996. (1996)

Chao NJ, Schriber J, Long GD, Negrin RS, Catolico M, Brown BW, Miller LL, and Blume KG. A randomized study of erythropoietin and G-CSF versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Blood, 83:2823-2828, 1994. (1994)

Snyder DS, Negrin RS, O'Donnell MR, Chao NJ, Amylon MD, Long GD, Nademanee AP, Stein AS, Parker PM, Smith EP, Somlo G, Margolin K, Lipsett JA, Hoppe RT, Slovak ML, Niland JC, Dagis AC, Wong RM, Forman SJ, and Blume KG. Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase. Blood, 84:1672-1679, 1994. (1994)

Chao NJ and Forman SJ. Allogeneic Bone Marrow Transplantation for Acute Lymphoblastic Leukemia. In: Bone Marrow Transplantation. Eds. Forman, S.J., Thomas, E.D. Blume, K.G., Blackwell Scientific Publications, Inc., New York, 1994. (1994)

Blume KG, Long GD, Negrin RS, Chao NJ, Kusnierz-Glaz C, and Amylon MD. The role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation. Bone Marrow Transplantation, 14 (Suppl 4) S9-10, 1994. (1994)

Chao NJ, Kastrissios H, Long GD, Negrin RS, Horning SJ, Wong RW, Blashke T;Blume KG. A new preparatory regimen for autologous bone marrow transplantation for patients with Hodgkin's and Non-Hodgkin's lymphoma. Cancer, 75:1354-9, 1995. (1995)

Negrin RS, Kusnierz-Glas CR, Still BJ, Schriber JR, Chao NJ, Long GD, Hoyle C, Hu WW, Horning SJ, Brown BW, Blume KG, and Strober S. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. Blood, 85:3334-3341, 1995. (1995)

Long GD, Negrin RS, Hoyle CF, Kusnierz-Glaz KR, Schriber JR, Blume KG, and Chao NJ. Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies. Cancer, 76:860-8, 1995. (1995)

Parker PM, Chao NJ, Snyder DS, Nademanee A, O'Donnell MR, Schmidt GM, Stein AS, Smith EP, Molina A, Stepan DE, Kashyap A, Planas I, Somlo G, Margolin K, Niland JC, Zwingenberger K, Wilsman K, Blume KG, and Forman SJ. Thalidomide therapy for chronic graft-versus-host disease. Blood, 86:3604-3609, 1995. (1995)

O'Donnell MR, Long GD, Parker PM, Niland J, Nademanee A, Amylon M, Chao NJ, Negrin RS, Schmidt GM, Slovak ML, Smith EP, Snyder DS,, Stein AS, Traweek T, Blume KG, Forman SJ. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. Journal of Clinical Oncology, 13:2973-2979, 1995. (1995)

Zaia JA, Schmidt GM, Chao NJ, Snyder DS, Nademanee A, O'Donnell MR, Stein AS, Smith EP, Molina A, Stepan DE, Kashyap A, Planas I, Somlo G, Margolin K, Niland JC, Blume KG, and Forman SJ. Pre-emptive ganciclivir based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: Long-term follow-up. Biology of Blood and Marrow Transplantation, 1:88-93, 1995. (1995)

Pattarelli P, Jeffrey RB, Chao N. Gallbladder wall thickening is neither sensitive nor specific for hepatic venoocclusive disease following bone marrow transplantation. Ultrasound International 1:163-4, 1995 (1995)

Chao NJ, and Blume KG. Reconstitution of hematopoiesis following allogeneic bone marrow transplantation. In: High Dose Cancer Therapy: Pharmacology, Hematopoietins and Stem Cells. Eds: Armitage, J.O., Antman, K.H., Williams and Wilkens, Baltimore, MD., 1995. (1995)

Chao NJ and Deeg HJ. In vivo prevention and treatment of GVHD. In Graft-versus-Host Disease. Eds: Ferrara, J.L.M., Deeg, H.J., and Burakoff S., Marcel Dekker, New York, NY, 1995. (1995)

Chao NJ, and Sackstein R. Veno-occlusive Disease. In The Kidney in Liver Disease. Ed: Epstein M. Elsevier, New York, 1995. (1995)

Chao NJ and Schlegel PG. Prevention and treatment of graft-versus-host disease. Ann NY Acad Sci, 770:130-140, 1995. (1995)

Schlegel PG, Chao NJ. Immunomodulatory peptides with high binding affinity for class II MHC molecules for the prevention of graft-versus-host disease. Leukemia and Lymphoma 18:179-184, 1996. (1996)

Schlegel PG, Aharoni R, Chen Y, Chen J, Teitelbaum D, Arnon R, Sela M, Chao NJ. A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo. Proceedings of the National Academy of Sciences (USA), 93:5061-5066, 1996. (1996)

Kusnierz-Glaz CR, Schlegel PG, Wong RM, Schriber JR, Chao NJ, Amylon MD, Hu WW, Negrin RS, Lee Y, Blume KG, and Long GD. The influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies. J Clin Oncol, 15 (1) 18-25, 1996. (1996)

Geiler CR, Baker J, Wells S, Schlegel PG, Chao NJ. Purging mobilized peripheral blood progenitor cells with 4-hydroxyperoxycyclophosphamide (4-HC). Cancer Research, Therapy and Control, 5 (1) 23-27, 1996. (1996)

Parker PM, Chao NJ, Ben-Ezra J, Slatkin N, Oppenshaw H, Niland J, Linker CA, Greffe BS, Kashyap A, Moliona A, Nademanee A, O'Donell MR, Planas I, Smith EP, Snyder DS, Stepan DE, Blume KG, and Forman SJ. Polymyositis as a manifestation of chronic graft-versus-host disease. Medicine 75 (5) 279-285, 1996. (1996)

Lee P, Zeng D, McCaulay , Chen YF, Geiler C, Umetsu DT, Chao N. T Helper 2-Dominant Antilymphoma Immune Response is Associated with Fatal Outcome. Blood, 90(4), 1611-1167, 1997. (1997)

Rizzieri DA, Chao N. Treatment of non-Hodgkin's lymphoma with high dose therapy and hematopietic stem cell support. Current Opinion in Oncology 9:420-427, 1997. (1997)

Kastrissios H, Chao NJ, Blaschke TF. Pharmacokinetics of high dose oral CCNU in bone marrow transplant patients. Cancer Chemotherapy and Pharmacology, in press. (1997)

Laughlin MJ, McGaughey DS, Crews JR, Chao NJ, Rizzieri D, Ross M, Gockerman J, Cirrincione C, Berry D, Mills L, Defusco P, LeGrand S, Peters WP, Vredenburgh JJ. Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant. J Clin Oncol 16:1008-1012, 1998 (1998)

Rizzieri DA, Chao NJ. Prevention and Treatments of graft-versus-host disease by pharmacologic agents. Current Opinion in Organ Transplantation 3: 105-111, 1998. (1998)

Watanabe N, Lu Q, DeRosa SC, Lee DC, Chao N, Mitra DK, Herzenberg LA, Herzenberg, LA, Shizura JA, Roederer M. Dynamics of Cytokine Expression in Memory CD4+ T Cells after Stem Cell Transplantation: Correlates of GVHD and CMV Disease. Submitted to Blood, 1998. (1998)

Ziske C, Märten A, Schöttker B, Buttgereit P, Schakowski F, Gorschlüter M, von Rücker A, Scheffold C, Chao NJ, Sauerbruch T, Schmidt-Wolf IGH. Resistance of pancreatic carcinoma cells is reversed by coculturing NK-like T cells with dendritic cells pulsed with tumor-derived RNA and CA 19-9. Molecular Therapy, 3(1):54-60, 2001. (2001)

Stuart MF, Chao NJ, Horning SF, Wong RM, Negrin RS, Johnston LF, Shizuru JA, Long GD, Blume KG, Stockerl-Goldstein KE. Efficacy and Toxicity of a CCNU-Containing High-Dose Chemotherapy Regimen followed by Autologous Hematopoietic Cell Transplantation in Relapsed or Refractory Hodgkin's Disease. Biology of Blood & Marrow Transplantation, 7:552-560, 2001. (2001)

McGaughey DS, Nikcevich DA, Long GD, Vredenburgh JJ, Rizzieri D, Smith CA, Broadwater G, Loftis JS, McDonald C, Morris AK, Folz FD, Chao NJ. Inhaled Steroids as Prophylaxis for Delayed Pulmonary Toxicity Syndrome in Breast Cancer Patients Undergoing High-Dose Chemotherapy and Autologous Stem Cell Transplantation Biology of Blood & Marrow Transplantation, 7:274-278, 2001. (2001)

Chao NJ, Blume KG, Forman SJ, Snyder DS. Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 1995 Jun 1;85(11):3353-4. (1995) Abstract

Chao NJ, Liu CX, Rooney B, Chen BJ, Long GD, Vredenburgh JJ, Morris A, Gasparetto C, Rizzieri DA. Nonmyeloablative regimen preserves "niches" allowing for peripheral expansion of donor T-cells. Biol Blood Marrow Transplant. 2002;8(5):249-56. (2002) Abstract

Bhalla KS, Wilczynski SW, Abushamaa AM, Petros WP, McDonald CS, Loftis JS, Chao NJ, Vredenburgh JJ, Folz RJ. Pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy with autologous hematopoietic support. Am J Respir Crit Care Med. 2000 Jan;161(1):17-25. (2000) Abstract

Lee PP, Zeng D, McCaulay AE, Chen YF, Geiler C, Umetsu DT, Chao NJ. T helper 2-dominant antilymphoma immune response is associated with fatal outcome. Blood. 1997 Aug 15;90(4):1611-7. (1997) Abstract

Chen BJ, Morris RE, Chao NJ. Graft-versus-host disease prevention by rapamycin: cellular mechanisms. Biol Blood Marrow Transplant. 2000;6(5A):529-36. (2000) Abstract

Snyder DS, Chao NJ, Amylon MD, Taguchi J, Long GD, Negrin RS, Nademanee AP, O'Donnell MR, Schmidt GM, Stein AS. Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission. Blood. 1993 Nov 1;82(9):2920-8. (1993) Abstract

Brodwater BK, Silber JS, Smith TP, Chao NJ, Suhocki PV, Ryan JM, Newman GE. Conversion of indwelling chest port catheters to tunneled central venous catheters. J Vasc Interv Radiol. 2000 Oct;11(9):1137-42. (2000) Abstract

Schlegel PG, Vaysburd M, Chen Y, Butcher EC, Chao NJ. Inhibition of T cell costimulation by VCAM-1 prevents murine graft-versus-host disease across minor histocompatibility barriers. J Immunol. 1995 Oct 15;155(8):3856-65. (1995) Abstract

Kühl JS, Sikic BI, Blume KG, Chao NJ. Use of etoposide in combination with cyclosporine for purging multidrug resistant leukemic cells from bone marrow in a mouse model. Prog Clin Biol Res. 1992;377:25-34. (1992) Abstract

Chao NJ, Parker PM, Niland JC, Wong RM, Dagis A, Long GD, Nademanee AP, Negrin RS, Snyder DS, Hu WW, Gould KA, Tierney DK, Zwingenberger K, Forman SJ, Blume KG. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. Biol Blood Marrow Transplant. 1996 May;2(2):86-92. (1996) Abstract

Long GD, Amylon MD, Stockerl-Goldstein KE, Negrin RS, Chao NJ, Hu WW, Nademanee AP, Snyder DS, Hoppe RT, Vora N, Wong R, Niland J, Reichardt VL, Forman SJ, Blume KG. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. Biol Blood Marrow Transplant. 1997 Dec;3(6):324-30. (1997) Abstract

Alvarnas JC, Negrin RS, Horning SJ, Hu WW, Long GD, Schriber JR, Stockerl-Goldstein K, Tierney K, Wong R, Blume KG, Chao NJ. High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2000;6(3A):352-8. (2000) Abstract

Chao NJ, Duncan SR, Long GD, Horning SJ, Blume KG. Corticosteroid therapy for diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. Ann Intern Med. 1991 Jan 15;114(2):145-6. (1991) Abstract

Kohler S, Hendrickson MR, Chao NJ, Smoller BR. Value of skin biopsies in assessing prognosis and progression of acute graft-versus-host disease. Am J Surg Pathol. 1997 Sep;21(9):988-96. (1997) Abstract

Boeckh M, Bowden RA, Storer B, Chao NJ, Spielberger R, Tierney DK, Gallez-Hawkins G, Cunningham T, Blume KG, Levitt D, Zaia JA. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001;7(6):343-51. (2001) Abstract

Chao NJ, Aihara M, Blume KG, Sikic BI. Modulation of etoposide (VP-16) cytotoxicity by verapamil or cyclosporine in multidrug-resistant human leukemic cell lines and normal bone marrow. Exp Hematol. 1990 Dec;18(11):1193-8. (1990) Abstract

Zaia JA, Schmidt GM, Chao NJ, Rizk NW, Nademanee AP, Niland JC, Horak DA, Lee J, Gallez-Hawkins G, Kusnierz-Glaz CR. Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: long-term follow-up. Biol Blood Marrow Transplant. 1995 Dec;1(2):88-93. (1995) Abstract

Kühl JS, Sikic BI, Blume KG, Chao NJ. Use of etoposide in combination with cyclosporin for purging multidrug-resistant leukemic cells from bone marrow in a mouse model. Exp Hematol. 1992 Oct;20(9):1048-54. (1992) Abstract

Behar E, Chao NJ, Hiraki DD, Krishnaswamy S, Brown BW, Zehnder JL, Grumet FC. Polymorphism of adhesion molecule CD31 and its role in acute graft-versus-host disease. N Engl J Med. 1996 Feb 1;334(5):286-91. (1996) Abstract

Chao NJ, Schriber JR, Grimes K, Long GD, Negrin RS, Raimondi CM, Horning SJ, Brown SL, Miller L, Blume KG. Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood. 1993 Apr 15;81(8):2031-5. (1993) Abstract

Rizzieri DA, Chao NJ. Treatment of non-Hodgkin's lymphoma with high-dose therapy and hematopoietic stem cell support. Curr Opin Oncol. 1997 Sep;9(5):420-7. (1997) Abstract

Forman SJ, Schmidt GM, Nademanee AP, Amylon MD, Chao NJ, Fahey JL, Konrad PN, Margolin KA, Niland JC, O'Donnell MR. Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia. J Clin Oncol. 1991 Sep;9(9):1570-4. (1991) Abstract

Horning SJ, Negrin RS, Hoppe RT, Rosenberg SA, Chao NJ, Long GD, Brown BW, Blume KG. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood. 2001 Jan 15;97(2):404-9. (2001) Abstract

McCune SL, Gockerman JP, Moore JO, Decastro CM, Bass AJ, Chao NJ, Long GD, Vredenburgh JJ, Gasparetto C, Adams D, Payne N, Rizzieri DA. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Leuk Lymphoma. 2002 May;43(5):1007-11. (2002) Abstract

Klein AK, Patel DD, Gooding ME, Sempowski GD, Chen BJ, Liu C, Kurtzberg J, Haynes BF, Chao NJ. T-Cell recovery in adults and children following umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2001;7(8):454-66. (2001) Abstract

Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant. 1999;5(6):347-56. (1999) Abstract

Chao NJ, Forman SJ, Schmidt GM, Snyder DS, Amylon MD, Konrad PN, Nademanee AP, O'Donnell MR, Parker PM, Stein AS. Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia during first complete remission. Blood. 1991 Oct 15;78(8):1923-7. (1991) Abstract

Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD, Nademanee AP, Negrin RS, O'Donnell MR, Parker PM. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med. 1993 Oct 21;329(17):1225-30. (1993) Abstract

Aihara M, Aihara Y, Schmidt-Wolf G, Schmidt-Wolf I, Sikic BI, Blume KG, Chao NJ. A combined approach for purging multidrug-resistant leukemic cell lines in bone marrow using a monoclonal antibody and chemotherapy. Blood. 1991 May 1;77(9):2079-84. (1991) Abstract

Schlegel PG, Chao NJ. Immunomodulatory peptides with high binding affinity for class II MHC molecules for the prevention of graft-versus-host disease. Leuk Lymphoma. 1996 Sep;23(1-2):11-6. (1996) Abstract

Chao NJ, Snyder DS, Jain M, Wong RM, Niland JC, Negrin RS, Long GD, Hu WW, Stockerl-Goldstein KE, Johnston LJ, Amylon MD, Tierney DK, O'Donnell MR, Nademanee AP, Parker P, Stein A, Molina A, Fung H, Kashyap A, Kohler S, Spielberger R, Krishnan A, Rodriguez R, Forman SJ, Bluzme KG. Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. Biol Blood Marrow Transplant. 2000;6(3):254-61. (2000) Abstract

Negrin RS, Kusnierz-Glaz CR, Still BJ, Schriber JR, Chao NJ, Long GD, Hoyle C, Hu WW, Horning SJ, Brown BW. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. Blood. 1995 Jun 1;85(11):3334-41. (1995) Abstract

Chao NJ, Nademanee AP, Long GD, Schmidt GM, Donlon TA, Parker P, Slovak ML, Nagasawa LS, Blume KG, Forman SJ. Importance of bone marrow cytogenetic evaluation before autologous bone marrow transplantation for Hodgkin's disease. J Clin Oncol. 1991 Sep;9(9):1575-9. (1991) Abstract

Laughlin MJ, McGaughey DS, Crews JR, Chao NJ, Rizzieri D, Ross M, Gockerman J, Cirrincione C, Berry D, Mills L, Defusco P, LeGrand S, Peters WP, Vredenburgh JJ. Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant. J Clin Oncol. 1998 Mar;16(3):1008-12. (1998) Abstract

Rizzieri DA, Long GD, Vredenburgh JJ, Gasparetto C, Morris A, Stenzel TT, Davis P, Chao NJ. Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen. Blood. 2001 Dec 1;98(12):3486-8. (2001) Abstract

Schlegel PG, Aharoni R, Chen Y, Chen J, Teitelbaum D, Arnon R, Sela M, Chao NJ. A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo. Proc Natl Acad Sci U S A. 1996 May 14;93(10):5061-6. (1996) Abstract

Chao NJ, Berry GJ, Advani R, Horning SJ, Weiss LM, Blume KG. Epstein-Barr virus-associated lymphoproliferative disorder following autologous bone marrow transplantation for non-Hodgkin's lymphoma. Transplantation. 1993 Jun;55(6):1425-8. (1993) Abstract

Chen BJ, Cui X, Liu C, Chao NJ. Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. Blood. 2002 May 1;99(9):3083-8. (2002) Abstract

Long GD, Chao NJ, Hu WW, Negrin RS, Wong RM, Blume KG. High dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma. Cancer. 1996 Dec 15;78(12):2502-9. (1996) Abstract

Advani R, Chao NJ, Horning SJ, Blume KG, Ahn DK, Lamborn KR, Fleming NC, Bonnem EM, Greenberg PL. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma. Ann Intern Med. 1992 Feb 1;116(3):183-9. (1992) Abstract

Schriber JR, Negrin RS, Chao NJ, Long GD, Horning SJ, Blume KG. The efficacy of granulocyte colony-stimulating factor following autologous bone marrow transplantation for non-Hodgkin's lymphoma with monoclonal antibody purged bone marrow. Leukemia. 1993 Oct;7(10):1491-5. (1993) Abstract

Stockerl-Goldstein KE, Horning SJ, Negrin RS, Chao NJ, Hu WW, Long GD, Hoppe RT, Amylon MD, Brown BW Jr, Wong RM, Blume KG. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 1996 May;2(2):76-85. (1996) Abstract

Schlegel PG, Aharoni R, Smilek DE, Fernandez LP, McDevitt HO, Tran N, Vaysburd M, Chao NJ. Prevention of graft-versus-host disease by peptides binding to class II major histocompatibility complex molecules. Blood. 1994 Oct 15;84(8):2802-10. (1994) Abstract

Hu WW, Long GD, Stockerl-Goldstein KE, Johnston LJ, Chao NJ, Negrin RS, Blume KG. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer. Clin Cancer Res. 1999 Nov;5(11):3411-8. (1999) Abstract

Chao NJ, Kastrissios H, Long GD, Negrin RS, Horning SJ, Wong RM, Blaschke TF, Blume KG. A new preparatory regimen for autologous bone marrow transplantation for patients with lymphoma. Cancer. 1995 Mar 15;75(6):1354-9. (1995) Abstract

Chen BJ, Cui X, Sempowski GD, Gooding ME, Liu C, Haynes BF, Chao NJ. A comparison of murine T-cell-depleted adult bone marrow and full-term fetal blood cells in hematopoietic engraftment and immune reconstitution. Blood. 2002 Jan 1;99(1):364-71. (2002) Abstract

Kühl JS, Durán GE, Chao NJ, Sikic BI. Effects of the methoxymorpholino derivative of doxorubicin and its bioactivated form versus doxorubicin on human leukemia and lymphoma cell lines and normal bone marrow. Cancer Chemother Pharmacol. 1993;33(1):10-6. (1993) Abstract

Kusnierz-Glaz CR, Schlegel PG, Wong RM, Schriber JR, Chao NJ, Amylon MD, Hu WW, Negrin RS, Lee Y, Blume KG, Long GD. Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies. J Clin Oncol. 1997 Jan;15(1):18-25. (1997) Abstract

Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Kwak LW, Long GD, Stallbaum B, O'Connor P, Blume KG. The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data. Ann Oncol. 1991 Jan;2 Suppl 1:47-50. (1991) Abstract

Gasparetto C, Gasparetto M, Morse M, Rooney B, Vredenburgh JJ, Long GD, Rizzieri DA, Loftis J, Chao NJ, Smith C. MOBILIZATION OF DENDRITIC CELLS FROM PATIENTS WITH BREAST CANCER INTO PERIPHERAL BLOOD STEM CELL LEUKAPHERESIS SAMPLES USING Flt-3-LIGAND AND G-CSF OR GM-CSF. Cytokine. 2002 Apr 7;18(1):8-19. (2002) Abstract

Schriber JR, Chao NJ, Long GD, Negrin RS, Tierney DK, Kusnierz-Glaz C, Lucas KS, Blume KG. Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation. Blood. 1994 Sep 1;84(5):1680-4. (1994) Abstract

Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Long GD, Hu WW, Wong RM, Brown BW, Blume KG. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood. 1997 Feb 1;89(3):801-13. (1997) Abstract

Rizzieri DA, Vredenburgh JJ, Jones R, Ross M, Shpall EJ, Hussein A, Broadwater G, Berry D, Petros WP, Gilbert C, Affronti ML, Coniglio D, Rubin P, Elkordy M, Long GD, Chao NJ, Peters WP. Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. J Clin Oncol. 1999 Oct;17(10):3064-74. (1999) Abstract

Fernandez LP, Schlegel PG, Baker J, Chen Y, Chao NJ. Does thalidomide affect IL-2 response and production? Exp Hematol. 1995 Aug;23(9):978-85. (1995) Abstract

Chao NJ, Timmerman L, McDevitt HO, Jacob CO. Molecular characterization of MHC class II antigens (beta 1 domain) in the BB diabetes-prone and -resistant rat. Immunogenetics. 1989;29(4):231-4. (1989) Abstract

Hu WW, Negrin RS, Stockerl-Goldstein K, Johnston LJ, Shizuru JA, Wong RM, Chao NJ, Long GD, Feiner RH, Blume KG. Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy. Biol Blood Marrow Transplant. 2000;6(1):58-69. (2000) Abstract

Snyder DS, Negrin RS, O'Donnell MR, Chao NJ, Amylon MD, Long GD, Nademanee AP, Stein AS, Parker PM, Smith EP. Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase. Blood. 1994 Sep 1;84(5):1672-9. (1994) Abstract

Kastrissios H, Chao NJ, Blaschke TF. Pharmacokinetics of high-dose oral CCNU in bone marrow transplant patients. Cancer Chemother Pharmacol. 1996;38(5):425-30. (1996) Abstract

Chen Y, Zeng D, Schlegel PG, Fidler J, Chao NJ. PG27, an extract of Tripterygium wilfordii hook f, induces antigen-specific tolerance in bone marrow transplantation in mice. Blood. 2000 Jan 15;95(2):705-10. (2000) Abstract

Parker P, Chao NJ, Ben-Ezra J, Slatkin N, Openshaw H, Niland JC, Linker CA, Greffe BS, Kashyap A, Molina A, Nademanee A, O'Donnell MR, Planas I, Sheibani K, Smith EP, Snyder DS, Spielberger R, Stein AS, Stepan DE, Blume KG, Forman SJ. Polymyositis as a manifestation of chronic graft-versus-host disease. Medicine (Baltimore). 1996 Sep;75(5):279-85. (1996) Abstract

Blume KG, Long GD, Negrin RS, Chao NJ, Kusnierz-Glaz C, Amylon MD. Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant. 1994;14 Suppl 4:S9-10. (1994) Abstract

Chen Y, Schlegel PG, Tran N, Thompson D, Zehnder JL, Chao NJ. Administration of a CD31-derived peptide delays the onset and significantly increases survival from lethal graft-versus-host disease. Blood. 1997 Feb 15;89(4):1452-9. (1997) Abstract

Chao NJ, Schriber JR, Long GD, Negrin RS, Catolico M, Brown BW, Miller LL, Blume KG. A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Blood. 1994 May 15;83(10):2823-8. (1994) Abstract